Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity

Purpose: Antineoplastic drugs, such as cisplatin (CDDP), are severely neurotoxic, causing disabling peripheral neuropathies with clinical signs known as chemotherapy-induced peripheral neurotoxicity. Cotreatment with neuroprotective agents and CDDP has been proposed for preventing or reversing the neuropathy. Erythropoietin given systemically has a wide range of neuroprotective actions in animal models of central and peripheral nervous system damage. However, the erythropoietic action is a potential cause of side effects if erythropoietin is used for neuroprotection. We have successfully identified derivatives of erythropoietin, including carbamylated erythropoietin, which do not raise the hematocrit but retain the neuroprotective action exerted by erythropoietin. Experimental Design: We have developed previously an experimental chemotherapy-induced peripheral neurotoxicity that closely resembles CDDP neurotoxicity in humans. The present study compared the effects of erythropoietin and carbamylated erythropoietin (50 μg/kg/d thrice weekly) on CDDP (2 mg/kg/d i.p. twice weekly for 4 weeks) neurotoxicity in vivo. Results: CDDP given to Wistar rats significantly lowered their growth rate (P < 0.05), with slower sensory nerve conduction velocity (P < 0.001) and reduced intraepidermal nerve fibers density (P < 0.001 versus controls). Coadministration of CDDP and erythropoietin or carbamylated erythropoietin partially but significantly prevented the sensory nerve conduction velocity reduction. Both molecules preserved intraepidermal nerve fiber density, thus confirming their neuroprotective effect at the pathologic level. The protective effects were not associated with any difference in platinum concentration in dorsal root ganglia, sciatic nerve, or kidney specimens. Conclusions: These results widen the spectrum of possible use of erythropoietin and carbamylated erythropoietin as neuroprotectant drugs, strongly supporting their effectiveness.

[1]  M. Stillman,et al.  Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.

[2]  G. Nicolini,et al.  Intraepidermal nerve fiber density in rat foot pad: neuropathologic–neurophysiologic correlation , 2005, Journal of the peripheral nervous system : JPNS.

[3]  E. Ferrannini,et al.  Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. , 2005, European heart journal.

[4]  A. Hoke,et al.  A novel endogenous erythropoietin mediated pathway prevents axonal degeneration , 2004, Annals of neurology.

[5]  S. Sallah,et al.  Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. , 2004, Cancer letters.

[6]  P. Ghezzi,et al.  Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Bokemeyer,et al.  EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. , 2004, European journal of cancer.

[8]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[9]  Justin C McArthur,et al.  The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.

[10]  P. Ghezzi,et al.  Erythropoietin both protects from and reverses experimental diabetic neuropathy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Zunino,et al.  Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Glass,et al.  Calpain inhibition protects against Taxol-induced sensory neuropathy. , 2003, Brain : a journal of neurology.

[13]  R. Myers,et al.  Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury , 2003, The European journal of neuroscience.

[14]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Buemi,et al.  The Pleiotropic Effects of Erythropoietin in the Central Nervous System , 2003, Journal of neuropathology and experimental neurology.

[16]  M. Gassmann,et al.  Erythropoietin‐induced excessive erythrocytosis activates the tissue endothelin system in mice , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  P. Lewczuk,et al.  Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.

[18]  S. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[19]  R. Myers,et al.  Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Gassmann,et al.  Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Eichler,et al.  Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. , 2000, Blood.

[24]  T. Golper,et al.  Impaired Biological Activity of Erythropoietin by Cyanate Carbamylation , 2000, Blood Purification.

[25]  G. Cavaletti,et al.  Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.

[26]  M. Miloso,et al.  Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats , 1999, Experimental Neurology.

[27]  D. Gershenson,et al.  Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. McArthur,et al.  Epidermal nerve fiber density: normative reference range and diagnostic efficiency. , 1998, Archives of neurology.

[29]  J. McArthur,et al.  Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy , 1998, Journal of neurology, neurosurgery, and psychiatry.

[30]  M. Markman,et al.  Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. , 1996, Gynecologic oncology.

[31]  J. Holst,et al.  Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy , 1996, Experimental Neurology.

[32]  G. Cavaletti,et al.  Protective effects of glutathione on cisplatin neurotoxicity in rats. , 1994, International journal of radiation oncology, biology, physics.

[33]  G. Cavaletti,et al.  Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. , 1994, In vivo.

[34]  K. L. Davis,et al.  Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. , 1993, European journal of biochemistry.

[35]  J. Arezzo,et al.  Nerve growth factor prevents experimental cisplatin neuropathy , 1992, Annals of neurology.

[36]  V. Lim.  Recombinant human erythropoietin in predialysis patients. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  J. Arezzo,et al.  Nerve growth factor prevents toxic neuropathy in mice , 1991, Annals of neurology.

[38]  N. Casadevall,et al.  Erythropoietin: physiology and clinical experience. , 1990, Seminars in hematology.

[39]  H. Kozutsumi,et al.  Chemical modification of erythropoietin: an increase in in vitro activity by guanidination. , 1990, Biochimica et biophysica acta.

[40]  A. Raine.  HYPERTENSION, BLOOD VISCOSITY, AND CARDIOVASCULAR MORBIDITY IN RENAL FAILURE: IMPLICATIONS OF ERYTHROPOIETIN THERAPY , 1988, The Lancet.

[41]  G. Cavaletti,et al.  Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration , 2004, Journal of Neuro-Oncology.

[42]  S. Muftuoglu,et al.  Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats , 2004, Medical oncology.

[43]  S. Lipton,et al.  Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  I. Barajon,et al.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats , 2004, Acta Neuropathologica.

[45]  R. Labianca,et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Cascinu,et al.  Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G. Cavaletti,et al.  Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. , 1994, Neurotoxicology.